Study Comparing Amitriptyline, Flunarizine, Topiramate, and Propranolol for Preventing Migraines in Primary Care Patients
- Participants:Adults
Rare diseases
Investigational molecules
Locations
Flunarizine hydrochloride is a medicine that belongs to several drug classes. It is described as a calcium channel blocker, a vasodilator, an antivertigo agent, and a histamine H1 receptor antagonist (an antihistamine).[3] Its Anatomical Therapeutic Chemical (ATC) classification code is N07CA03, which places it among antivertigo preparations.[4] The substance is also known as flunarizine, flunarizine dihydrochloride, and by the development code R 14950.[4] Brand names include Sibelium, Flunarin, Migon and numerous others marketed in countries across Asia, Latin America and Europe.[4] Flunarizine hydrochloride is an authorised medicine in several countries, but in the European Union clinical trial described here it is being studied as a preventive treatment for migraine.[1]
Flunarizine is a selective calcium entry blocker. It blocks the movement of calcium into cells, which can reduce the excessive electrical activity in the brain that is thought to contribute to migraine.[3] It also has calmodulin binding properties and acts as a histamine H1 receptor antagonist, meaning it blocks some of the effects of histamine in the body.[3] As a vasodilator, it widens blood vessels, which may also play a role in preventing migraine attacks.[4]
Flunarizine is taken by mouth. The clinical trial uses a 10 mg oral dose.[1] Pharmaceutical forms that exist for flunarizine include 5 mg capsules, 5 mg tablets, 10 mg tablets and 20 mg tablets.[2]
One Phase 3 clinical trial is registered for flunarizine hydrochloride in migraine. The trial is authorised but not yet recruiting, so no results are available yet.[1] The study plans to enrol 460 participants and compares four preventive medicines: amitriptyline, flunarizine, topiramate and propranolol.[1] Flunarizine is given at a 10 mg oral dose in this study.[1]
The main thing the trial measures is clinical effectiveness, defined as the change in the mean number of monthly migraine days (MMD) after 12 weeks of treatment compared with the number before treatment started.[1] The trial is designed to find out whether flunarizine, amitriptyline or topiramate is more effective than propranolol, which is used as the comparison medicine.[1]
The sources provided for this page do not include a list of side effects for flunarizine hydrochloride.
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.